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Abstract
Congenital muscular dystrophy (CMD) is a clinically and genetically heterogeneous group of inherited muscle disorders. In
patients, muscle weakness is usually present at or shortly after birth and is progressive in nature. Merosin deficient
congenital muscular dystrophy (MDC1A) is a form of CMD caused by a defect in the laminin-a2 gene (LAMA2). Laminin-a2i s
an extracellular matrix protein that interacts with the dystrophin-dystroglycan (DGC) complex in membranes providing
stability to muscle fibers. In an N-ethyl-N-nitrosourea mutagenesis screen to develop zebrafish models of neuromuscular
diseases, we identified a mutant fish that exhibits severe muscular dystrophy early in development. Genetic mapping
identified a splice site mutation in the lama2 gene. This splice site is highly conserved in humans and this mutation results in
mis-splicing of RNA and a loss of protein function. Homozygous lama2 mutant zebrafish, designated lama2
cl501/cl501,
exhibited reduced motor function and progressive degeneration of skeletal muscles and died at 8–15 days post fertilization.
The skeletal muscles exhibited damaged myosepta and detachment of myofibers in the affected fish. Laminin-a2 deficiency
also resulted in growth defects in the brain and eye of the mutant fish. This laminin-a2 deficient mutant fish represents
a novel disease model to develop therapies for modulating splicing defects in congenital muscular dystrophies and to
restore the muscle function in human patients with CMD.
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Introduction
Congenital muscular dystrophies (CMDs) are a clinically and
genetically heterogeneous group of neuromuscular disorders that
typically present at birth or in early infancy with hypotonia,
muscle weakness, and histological evidence of a dystrophic
myopathy [1,2,3,4]. MDC1A is a specific form of CMD
associated with absence or reduction of laminin-a2 in skeletal
muscle [5,6]. MDC1A, which represents approximately 50% of
CMD cases, is caused by recessive mutations in the LAMA2
gene encoding the a2 chain of laminin [6]. More than
800 mutations in the LAMA2 gene have been identified to date
in both coding as well as non-coding sequences (www.dmd.nl).
In addition to the skeletal muscle defects, the brains of MDC1A
patients exhibit white matter abnormalities that appear in many
patients after 2 years of age. Epilepsy and focal cortical
dysplasia leading to cognitive deterioration have also been seen
in patients affected with MDC1A [7,8,9]. Patients with LAMA2
mutations exhibit feeding problems and/or respiratory difficul-
ties and often require feeding tube placement or ventilator
assistance in severe cases [10].
Laminins are a family of large extracellular glycoproteins.
Laminin-a2 is specifically expressed in the basal lamina of striated
muscles and peripheral nerves. Laminin-a2 interacts with laminins
b1, c1o rb2 to form laminin 211 and 221 heteromers in the basal
lamina [11,12]. These laminin complexes interact with a-
dystroglycan at the surface of myofibers, resulting in stabilization
of the sarcolemma as mutations abolishing these interactions are
associated with inability of muscles fibers to adhere to the
basement membrane [13]. Laminins also play a significant role in
muscle repair as laminin-a2 deficient muscles exhibit a reduction
in proliferative ability of satellite cells and inability to regenerate
[14,15]. A number of animal models of laminin-a2 deficiencies
have been developed. In mice, a complete loss of laminin-a2
results in severe muscular dystrophy and growth retardation while
missense or splice-site mutations resulting in truncated Lama2
protein in muscle cause a less severe phenotype [16,17,18].
Laminin-a2 deficiency is also associated with muscular dystrophy
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changes in animal models as seen in human patients suggest an
evolutionary conservation of laminin-a2 function in vertebrate
muscles [20].
MDC1A is associated with severe disability and shorter lifespan
and no specific therapies are available to treat this disease. While
targeted therapeutic developments using murine models appear to
be promising, testing a large number of drugs in mice can be very
slow, signifying the need to develop animal models that can be
used for high throughput therapeutic screens. In the past decade,
zebrafish have emerged as a powerful genetic model to study
diseases and to develop therapies due to high genomic similarity
with humans, small size, fast reproductive rates and ease of doing
high throughput drug screens [21,22,23,24]. Therefore, we
performed an N-ethyl-N-nitrosourea (ENU) mutagenesis screen
in zebrafish to develop vertebrate animal models of neuromuscular
diseases to enable the appraisal of early pathological processes and
subsequent trial of therapeutic approaches. This study describes
the genetic mapping and characterization of a mutant zebrafish
line with a novel splice site mutation in the lama2 gene causing
muscular dystrophy and growth defects. These mutant fish model
the disease pathology associated with human CMD patients and
will be a novel disease model to test therapies based on splicing-
modulation as well as performing high throughput chemical
screens.
Results
A Severe Muscular Dystrophy in Zebrafish Results Due to
a Splice Site Mutation in Lama2 Gene
A forward genetic screen to identify genes involved in
neuromuscular disorders using zebrafish resulted in the identifi-
cation of a mutant that exhibited severe muscular dystrophy. Wild-
type embryos displayed highly birefringent skeletal muscles
indicative of organized sarcomeric structure within muscle fibers.
The mutant fish, however, displayed patchy birefringence
suggesting highly degenerative skeletal muscles evident by 3 days
post fertilization (dpf) (Fig. 1A). This dystrophic phenotype was
much more severe than seen in dystrophin or dystroglycan null
zebrafish mutants where extensive muscle degeneration becomes
prominent later in development (4–5 dpf) [13,25]. The muscle
degeneration progressed to most of the somites by 5 dpf (Fig. 1A).
The mutant fish exhibit reduced mobility in comparison to the
wild-type fish. In an embryo swirl assay, swirling of petri dish
containing embryos results in collection of embryos in the middle
of the dish due to forces around the edge of the dish. As the
swirling motion stops, embryos exhibit a swimming response
towards the periphery of the dish. After cessation of swirling, the
total number of wild-type and mutant embryos that remained in
the middle of the dish (3 cm diameter) was counted. While, most
of the wild-type embryos swam out of the middle circle
immediately (82.89% escaped, n=110), a large number of mutant
embryos failed to swim out of the circle (41.94% escaped, n=38)
demonstrating reduced motility. The motor function of muscle
was also assessed using touch evoked response assay. Mutant fry
invariably exhibited slower swimming behavior than their wild
type clutch-mates in touch-evoke response assay (wild-type:
4.861.1 cm/0.1 s, n=6; mutant: 1.260.6 cm/0.1 s, n=6; Videos
S1 and S2). These data demonstrate that mutation in these fish
results in impaired motor function. Heterozygous fish appeared
unaffected and had normal lifespans and fecundity while
homozygous mutant fish invariably died between 8–15 dpf, much
before they attain reproductive age.
To identify the mutant locus, genetic mapping of the dystrophic
phenotype was performed using SSLP markers. An initial bulk
segregant analysis mapped the putative gene to chromosome 20
between z13867 (22.3 cM) and z7603 (27.2 cM). An analysis of
this genomic area (4.9 cM) identified lama2 as a potential
candidate gene (Fig. 1B). Therefore genetic complementation
analysis was performed by crossing the mutant fish line with
a previously known fish mutant of lama2
tk209 (candyfloss) [20]. These
mutants failed to genetically complement each other suggesting
a mutation in the same gene. To identify the mutation in lama2
gene (herein designated lama2
cl501), genomic sequencing was
performed that identified a point mutation in c.5376+1G.Aa t
a donor splice site in intron 33 (Fig. 1C). This G is 100%
conserved in all vertebra examined and any base change at this
position results in aberrant splicing of mRNA [26]. This splice site
further showed high homology to the consensus sequence in the
human LAMA2 gene (Fig. 1D).
To understand the effect of this mutation on splicing, RT-PCR
analysis was performed in wild-type and mutant fish. RT-PCR
using primers specific for exons 33 and 34 showed the presence of
a larger PCR product in the mutant fish in comparison to wild-
type fish (Fig. 1E). Sequencing of this PCR product from
lama2
cl501/cl501 fish identified an insertion of 764 base pairs of
intron 33 in the mutant fish (Fig. 1F). Insertion of this intronic
sequence resulted in a frame-shift mutation and generation of stop
codon in the mutant laminin-a2 mRNA corresponding to the long
arm coiled-coil in the protein that is required to interact with b-
and c- laminins to form the laminin complex in basal lamina
(Fig. 1G, arrow). Western blotting using a laminin-a2 antibody
identified an expected size high molecular weight protein band
(,400kDa) in wild-type fish, which was reduced in the mutant fish
(,90%) (Fig. 1H). This suggests that the splice site mutation in the
lama2 gene resulted in a loss of protein function in mutant
zebrafish.
Lama2
cl501/cl501 Zebrafish Exhibit Damaged Myosepta and
Detached Myofibers in Muscles
To identify the pathological changes in the skeletal muscles of
lama2
cl501/cl501 mutant fish, histological analysis was performed by
hematoxylin and eosin staining at 5 dpf. Analysis of longitudinal
sections identified multiple abnormalities in the skeletal muscles of
the mutant fish (Fig. 2A–B). Lama2
cl501/cl501 fish displayed
muscular atrophy with disrupted myosepta in most of their
somites (Fig. 2B, arrowhead). In addition, several detached
myofibers were seen to be present in the mutant fish (Fig. 2B,
arrow). Cross-sections of wild-type and mutant fish revealed
smaller myotomes in the mutant fish in comparison to the wild-
type fish (Fig. 2C–D). Cross-sections of the mutant muscles also
showed eosin positive hypercontracted damaged myofibers in-
dicative of dystrophic muscles (Fig. 2D, arrows).
Laminin-a2 Deficient Zebrafish have Extracellular Matrix
Defects in the Skeletal Muscles
To identify the ultra-structural changes in skeletal muscles due
to laminin-a2 deficiency, electron microscopy was performed in
the control and lama2
cl501/cl501 fish. In wild-type fish, laminin is
expressed in the extra-cellular matrix at the myotendinous
junction (MTJ). Components of the dystrophin-DGC complex
are expressed at the end of myofibers that attach to the MTJ
during early zebrafish development. The myotome of wild-type
muscles exhibited well -organized extra cellular matrix (Fig. 2E).
Mutant fish exhibited highly damaged MTJ with thickening of
extracellular areas and accumulation of electron dense collagen
A Splice-Site Model of Laminin-a2 Deficiency
PLOS ONE | www.plosone.org 2 August 2012 | Volume 7 | Issue 8 | e43794A Splice-Site Model of Laminin-a2 Deficiency
PLOS ONE | www.plosone.org 3 August 2012 | Volume 7 | Issue 8 | e43794fibers and branching projections. (Fig. 2H, arrow). The myofibers
that remained attached to the myosepta further showed disorga-
nized Z- and M-lines in the contractile apparatus without any
sarcolemmal defects (Fig. 2F and 2I). Cross-sectional views of the
muscle revealed detachment of myofibers from the surrounding
basement membrane and accumulation of abnormal membrane
vesicles that are absent in wild-type muscles, as well as apoptotic
nuclei (Fig. 2G and 2J, arrow), suggesting the presence of necrotic
fibers.
To understand the molecular effect of laminin-a2 deficiency on
muscle, whole mount immunofluorescence was performed at 5
dpf. Immunofluorescence using a pan anti-laminin antibody
showed that the overall expression of laminins was reduced in
the mutant muscles. This implies that loss of laminin-a2
destabilizes the laminin complex in basal lamina in zebrafish
(Fig. 3A–B). The expression of membrane b-dystroglycan and
dystrophin was also reduced in the mutant fish (Fig. 3C–F).
Immunofluorescence in a large number of embryos revealed
a direct correlation between muscle degeneration and reduction of
sarcolemmal proteins and highly reduced levels of sarcolemmal
proteins were seen in more severely affected embryos. Immuno-
fluorescence staining for a-actinin and actin also detected highly
disorganized muscles with hypercontracted myofibers lacking
myofibrillar organization in the muscles of the mutant fish,
indicative of severe muscle degeneration in the skeletal muscle
(Fig. 3G–J). To examine if the sarcolemmal damage is a direct
result of lama2 deficiency or is a secondary consequence of
extensive fiber necrosis, Evans blue dye (EBD) injections were
performed in live zebrafish embryos during early development
stage at 3 dpf. Analysis of mutant somites failed to detect any EBD
positive intact myofibers in the mutant fish except the occasional
dye signal from the necrotic fibers (Figure 3K). This suggests that
sarcolemmal damage observed in lama2 mutant fish is due to
extensive muscle necrosis during advanced stages of disease
progression.
Lama2 Mutant Fish Exhibit Growth Abnormalities
Laminin-a2 deficiency in humans is associated with brain
abnormalities. Therefore, to identify any brain defects associated
with laminin-a2 deficiency in zebrafish, histological analysis of the
lama2
cl501/cl501 CNS was performed using hematoxylin and eosin
staining (Fig. 4A–B and 4E–F). A comparison of brain histology in
several embryos showed a consistent reduction in the size of brain
in the mutant fish (1165.81%) at 7 dpf. The cells in the mutant
brain appeared to be clumped in comparison to the wild-type fish.
Further, a comparison of eyes in wild-type and mutant fish also
consistently revealed smaller eyes (1667.83%) in the mutant fish
with compressed cellular layers (Fig. 4C–D and 4G–H). Similar to
the brain, cells in the ganglion layer in the eye appeared to be
tightly clumped in the mutant fish as compared to the wild-type.
This is consistent with the previously published reports of growth
retardation in mice in laminin-a2 deficiency, suggesting that
similar processes may be altered in zebrafish [16].
Discussion
Congenital muscular dystrophies represent a severe group of
muscular dystrophy for which no treatment is available. Here we
describe a novel splice site mutant of laminin-a2 deficiency
modeling congenital muscular dystrophies as seen in human
patients. Of more than 700 pathogenic mutations reported in the
human LAMA2 gene, 30–40% of mutations are present within
splice sites (www.dmd.nl). We show here that a novel splice-site
mutation in lama2 in zebrafish results in muscular dystrophy as
well as brain and eye abnormalities. There are several animal
models of laminin-a2 available that exhibit mild to severe form of
dystrophy depending on the nature of mutation, including dy2J
mice that have a splice-site mutation [16,18,20]. However, the
consequences of splice site mutation in lama2
cl501/cl501are different
from those in the dy2J mice and are in a distinct species/model
system. In dy2J mice, another alternative splice site is used by the
splicing machinery causing the expression of a smaller protein
lacking 55 amino-acids in the domain IV. Expression of this
smaller laminin-a2 protein results in a milder form of dystrophy in
dy2J mice as compared to dy3k mice that have a null mutation.
The splice site mutation of lama2
cl501/cl501 zebrafish results in an
intron retention and a corresponding frameshift mutation leading
to generation of a stop codon and a complete lack of laminin-a2
protein, resembling a null mutation. Both of these splice site
mutants result in different degrees of lama2 expression (partial vs.
null), as well as disease severity, representing distinct disease
models. It has also been shown that candyfloss fish has a nonsense
mutation in the C-terminal domain of Lama2 resulting in
dystrophic muscles [20]. While the disease pathology of
lama2
cl501/cl501 is similar to candyfloss mutant, two mutations are
different at the molecular levels.
In human MDC1A, a phenotype-genotype correlation is often
seen as partial deficiency of protein leads to a milder form of the
disease and complete loss of function results in severe muscle and
brain abnormalities [27]. In recent years, large efforts have been
made to develop therapies based on splice-modulation. A success-
ful application of this approach is seen in Duchenne muscular
dystrophy where skipping of mutant exon by antisense oligonu-
cleotides results in restoration of open reading frame and a smaller
functional protein with less severe Becker muscular dystrophy.
This approach is currently in clinical trials for exon 51 skipping in
Duchenne muscular dystrophy [28,29]. In several other disorders,
splice modulation by restoring cryptic splicing, tweaking alterna-
tive splicing or inducing exon inclusion has already been shown to
have great potential for treating diseases [30,31]. Studies have also
identified several classes of chemicals that can correct the splicing
defects and will be attractive to test in our zebrafish models for
future studies [32]. Therefore, lama2
cl501/cl501 zebrafish model will
be a valuable tool in testing therapies aimed in correcting the
muscle defects and decreasing disease severity in patients affected
with splice-site mutations in LAMA2 gene. The small size, rapid
ex-vivo development, and live analysis of zebrafish embryos during
Figure 1. Morphological, genetic and molecular characterization of lama2
cl501/cl501 zebrafish. (A) In comparison to the wild-type fish,
lama2
cl501/cl501 fish exhibit smaller bodies (left panel) and displayed muscle disorganization early in development at 3 dpf (right panel). The muscle
degeneration progressed to most of the somites by 5 dpf. (B) Genetic mapping in mutant fish associated the linkage of mutant locus in 4.9 cM region
on chromosome 20 in zebrafish identifying lama2 as the candidate gene. (C) Sequencing of lama2 gene in zebrafish identified a mutation at
c.5376+1G.A in the mutant fish (arrow). (D) The consensus splice site containing the mutation is highly conserved in human LAMA2 gene. (E) RT-PCR
using primers specific for the exons 33 and 34 on either side of the mutant intronic sequence showed a larger PCR product (,900 base pairs) in the
mutant fish in comparison to the wild-type fish (152 base pairs) suggesting aberrant splicing. (F) Sequencing of the RT-PCR products revealed the
retention of 764 base pairs of intron 33 in the mutation fish (arrow). (G) This mutation is localized at the long arm coiled-coil of lama2 protein (arrow)
that interacts with b- and c- laminins to form functional laminin complex (H) Western blotting analysis showed a reduction of laminin-a2 protein in
the mutant fish.
doi:10.1371/journal.pone.0043794.g001
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much faster than it would be using higher vertebrate animal
models. The lama2
cl501/cl501 fish have a severe and easily assayable
phenotype that will provide robust endpoints, such as birefrin-
gence, reduced motility and increased mortality, for testing
potential therapies. In addition, therapies aimed at restoring the
muscle function in mutant fish by modulating pathways directly or
indirectly regulating laminin-a2 function and/or stabilizing the
detaching myofibers from extracellular matrix, will potentially be
applicable in treating human patients affected with MDC1A.
Figure 2. Abnormal myosepta and myofiber detachment in laminin-a2 deficient lama2
cl501/cl501 fish. (A & B) Hematoxylin and eosin
staining of longitudinal sections of wild-type and lama2 mutant fish at 5 dpf. Mutant muscles showed highly disorganized myofibers in the affected
somites with irregular myosepta boundaries (arrowhead) and eosin positive detached myofibers (arrow). (C–D) Cross-sections of wild-type and
mutation fish also showed smaller myotome and degenerating muscle fibers in lama2 mutant fish at 5 dpf (arrows), bars =10 mm. (E & H) Electron
microscopy showed myofiber detachment from the myotendinous junction (MTJ) in mutant muscles (arrow). (F & I) The myofibers in wild-type
muscles attached tightly to the surrounding fibers while mutant muscle displayed large gaps in the extracellular matrix between adjacent fibers and
disorganized Z- lines (black arrow) and M-lines (while arrow). (G & J) Defects in extracellular-matrix results in damaged myofibers in the myotome
(cross-section). A large number of apoptotic nuclei were observed in the mutant muscles (J, arrow).
doi:10.1371/journal.pone.0043794.g002
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PLOS ONE | www.plosone.org 5 August 2012 | Volume 7 | Issue 8 | e43794Figure 3. Laminin-a2 deficiency results in severe muscle degeneration. (A–B) Wholemount immunofluorescence analysis showed reduced
levels of laminin complex in myotendinous junctions in the mutant muscles. (C–F) The expression of b-dystroglycan as well as dystrophin was also
reduced in the mutant muscles. (G–J) Myofibers in wild-type muscles are attached to either side of the myotendinous junctions and displayed well-
organized muscles. Mutant fish, however, displayed highly disorganized muscles. Several detached myofibers lacking the contractile proteins are
seen in the mutant muscles by a-actinin and sarcomeric actin antibody staining (arrows). (K) Evans blue dye (EBD) injections at 3 dpf detected
occasional staining in necrotic fibers (arrow). Bars =10 mm.
doi:10.1371/journal.pone.0043794.g003
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a great potential for treatment of MDC1A by upregulation of
Lama1 or integrins in the muscle [33,34]. Therefore, identification
of chemicals that can upregulate these pathways will be helpful for
treating patients with Lama2 deficiency. Further these therapies
will be tested in candyfloss mutants as well as different mouse
models for their robustness in muscle improvement.
The lama2
cl501/cl501 mutant fish showed similar pathological
defects in the extra-cellular matrix and extensive myofiber damage
to those seen in human patients. Similar to the neonatal onset of
the disease in human patients, lama2
cl501/cl501 fish also exhibited
muscle degeneration early in development (3 dpf). Moreover, no
regenerative muscles fibers were detected in the skeletal muscles of
the affected fish. No sarcolemmal defects were seen during earlier
stages of disease pathogenesis as seen by a lack of EBD staining
which is similar to a previously published study in candyfloss fish
that showed extracellular matrix defects are not associated with
sarcolemmal damages in zebrafish. Although it is not practical to
perform EBD injections at later ages, ultrastructural and
immunohistochemical studies during later stages revealed de-
velopment of extensive degeneration of skeletal muscles in
lama2
cl501/cl501 fish with a corresponding reduction in b-dystrogly-
can and dystrophin expression. Hayashi et al., have shown that in
a severe congenital form of MDC1A, extensive muscle de-
generation during neonatal phases results in activation of
membrane attack complex (MCA) that immunolocalized to
myofibers showing highly reduced levels of b-dystroglycan and
dystrophin suggesting that degenerating myofibers start to lose the
immunoreactivity of sarcolemmal proteins [35]. Similarly, another
study reported a patient exhibiting deficiency of Lama2 also
exhibited low levels of dystrophin, suggesting sarcolemmal damage
may be secondary to ECM defects that manifest in highly
degenerative and necrotic fibers [36]. These observations suggest
that, similar to human patients, early dystrophic changes in fish
involve extra-cellular matrix defects and fiber detachment without
significant damage to the sarcolemma. With disease progression,
extensive myofiber damage and necrosis results in a reduction of
sarcolemmal proteins in the affected muscles in zebrafish as has
been seen in severe congenital forms of the disease in humans [35].
This mode of muscle damage is quite distinct from sapje fish
harboring a mutation in dystrophin where sarcolemmal damage is
evident during early phases of disease progression [25].
The laminin-a2 deficient fish also exhibited a reduction in body
size as seen in the muscle, brain and eyes. Previously, it has been
shown that complete knockout of Lama2 in mice resulted in
a generalized growth retardation and severe muscular dystrophy
and death by 5 weeks of age [16] suggesting similar pathological
processes being altered in all vertebrate models. In the murine
model, laminin deficiency has been shown to cause delayed
oligodendrocyte maturation and contribute to the CNS defects
seen in MDC1A [37]. However, no significant structural
abnormalities were observed in the brains of laminin-a2 deficient
fish by 5 dpf considering strong expression of lama2 transcripts is
seen in muscle, eye and brain of developing zebrafish embryos
[38]. In MDC1A, the white matter defects are normally seen after
six months or later in human patients. A lack of detection of
similar changes in the zebrafish brain could be due to early
lethality of lama2 mutations before such processes become
apparent in zebrafish and require future investigation.
As lama2
cl501/cl501 mutant fish recapitulate the pathological
findings and muscle defects seen in MDC1A, we propose this
novel splice site zebrafish mutant will be an invaluable vertebrate
animal model for developing therapies and improving muscle
function in the congenital muscular dystrophies.
Materials and Methods
Fish Maintenance
Fish were bred and maintained using standard methods as
described [39]. Wild-type embryos were obtained from the
Figure 4. Lama2
cl501/cl501 fish exhibit growth abnormalities. (A & E) Histological analysis of cross-section at 7 dpf revealed smaller brain in the
mutant fish in comparison to wild-type fish. (B & F) Magnified views of brains showing tightly clumped cells in the mutant brains. (C & G) Wild-type as
well as mutant fish displayed well-organized cellular layers in eyes. (D & H) Magnified views of the ganglion cell layer showed tightly organized cells
with reduced extracellular space between the cellular layers in mutant fish in comparison to the wild-type.
doi:10.1371/journal.pone.0043794.g004
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28.5uC. All animal work was performed with approval from the
Children’s Hospital Boston Animal Care and Use Committee (11-
05-1955R).
ENU Screen
The ENU mutagenesis screen was performed as described
earlier [13]. Zebrafish larvae were screened at 3–4 dpf using
a birefringence assay. Crosses in which approximately 25%65%
of larvae showed patchy or reduced birefringence of their axial
skeletal muscles in polarized light were identified as potential
skeletal muscle mutants and these families were selected for further
study (n=70–200).
Motility Assay
Embryo swirl assay was performed by swirling the petri dishes
containing wild-type and mutant embryos till all the embryos
collected in the middle of the dish. As the water whorl is stopped,
total number of embryos left in the middle of the dish (3 cm
diameter) was counted (n=60–150).
For touch evoke response assay, mechanosensory stimuli were
delivered to 3 dpf embryo tails using insect pins. Time-lapse
images of zebrafish embryos were takes at different time intervals
using a Nikon smz1500 microscope with SPOT camera system.
The length of time for each fish to leave the frame of view was
averaged across fish (n=6) [13].
Genetic Mapping
Mutant heterozygous zebrafish (AB strain) were out-crossed to
wild-type wik to generate polymorphic mapping strains. Low-
resolution mapping was done with 40 diploid mutant and 40
diploid wild-type embryos obtained from in-crossing mapping F2
fish. Microsatellite CA markers throughout the genome were used
to scan for linkage as described [40]. Complementation analysis
was performed to determine if this mutant fish and lama2
tk209
(candyfloss) were allelic by crossing heterozygous fish. Mutant
embryos were evaluated by birefringence assay. Genomic
sequencing was performed in wild-type and mutant fish using
primers spanning the complete lama2 gene in zebrafish (Pubmed
accession Number: JN786913.1). As the sequence of zebrafish
lama2 gene was already known, no new sequence was generated.
Therefore, no sequence was submitted to GenBank.
RNA Extraction and RT-PCR
RNA was isolated from pools of (3–5) mutant or wild-type
embryos at 5 dpf using RNeasy fibrous tissue mini kit (Qiagen).
cDNA was prepared using Superscript III first-strand synthesis kit
(Invitrogen). Equal concentrations of wild-type and mutant RNA
were used for cDNA synthesis. RT-PCR was performed using
exonic primers and PCR products were analyzed in using the
HAD-GT12 Genetic Analyzer (Qiagen).
Histology, Immunofluorescence
Fish embryos and larvae were anesthetized and fixed overnight
in 4% paraformaldehyde in PBS at 4uC. For histology, 5 um thin
paraffin sections were cut stained with hematoxylin and eosin
(Rodent Histopathology Core, Harvard Medical School). Immu-
nofluorescence was performed using the protocol described
previously [13]. Whole mount immunofluorescence was per-
formed on wild-type and mutant embryos (15–20) as described
[13].
Primary antibodies used in this study were: b-dystroglycan
(Novocastra, NCL-b-DG), laminin-a2 (Sigma, HPA005537),
dystrophin (Sigma, D8043), laminin (Sigma, L9393), a-actinin;
clone EA-53 (Sigma, A7811). Nuclear staining was done using
DAPI. Secondary antibodies were purchased from Jackson
ImmunoResearch.
Electron Microscopy
Zebrafish embryos (n=8–10) were fixed in formaldehyde-
glutaraldehyde-picric acid in cacodylate buffer overnight at 4uC
followed by osmication and uranyl acetate staining. Subsequently,
embryos were dehydrated in a series of ethanol washes and finally
embedded in Taab epon (Marivac Ltd., Nova Scotia, Canada).
95 nm sections were cut with a Leica ultracut microtome, picked
up on 100 m formvar coated Cu grids and stained with 0.2% lead
citrate. Sections from 3–4 embryos were viewed and imaged under
the Philips Tecnai BioTwin Spirit Electron Microscope (Electron
Microscopy Core, Harvard Medical School).
Supporting Information
Video S1 Touch evoke response assay in wild-type
embryos at 5 dpf.
(MP4)
Video S2 Touch evoke response assay in lama2 mutant
fish at 5 dpf.
(MP4)
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